Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.
Li K, Tandurella JA, Gai J, Zhu Q, Lim SJ, Thomas DL 2nd, Xia T, Mo G, Mitchell JT, Montagne J, Lyman M, Danilova LV, Zimmerman JW, Kinny-Köster B, Zhang T, Chen L, Blair AB, Heumann T, Parkinson R, Durham JN, Narang AK, Anders RA, Wolfgang CL, Laheru DA, He J, Osipov A, Thompson ED, Wang H, Fertig EJ, Jaffee EM, Zheng L. Li K, et al. Among authors: parkinson r. Cancer Cell. 2022 Nov 14;40(11):1374-1391.e7. doi: 10.1016/j.ccell.2022.10.001. Epub 2022 Oct 27. Cancer Cell. 2022. PMID: 36306792 Free PMC article.
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, Cao H, Zhang T, Gai J, Celiker B, Zhu Q, McPhaul T, Durham J, Purtell K, Klein R, Laheru D, De Jesus-Acosta A, Le DT, Narang A, Anders R, Burkhart R, Burns W, Soares K, Wolfgang C, Thompson E, Jaffee E, Wang H, He J, Zheng L. Heumann T, et al. Among authors: parkinson r. Nat Commun. 2023 Jun 20;14(1):3650. doi: 10.1038/s41467-023-39196-9. Nat Commun. 2023. PMID: 37339979 Free PMC article.
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.
Wang J, Gai J, Zhang T, Niu N, Qi H, Thomas DL 2nd, Li K, Xia T, Rodriguez C, Parkinson R, Durham J, McPhaul T, Narang AK, Anders RA, Osipov A, Wang H, He J, Laheru DA, Herman JM, Lee V, Jaffee EM, Thompson ED, Zhu Q, Zheng L. Wang J, et al. Among authors: parkinson r. Sci Adv. 2024 Feb 9;10(6):eadk1827. doi: 10.1126/sciadv.adk1827. Epub 2024 Feb 7. Sci Adv. 2024. PMID: 38324679 Free PMC article.
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients.
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz HJ, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, El Khoueiry A, Azad NS. Lee V, et al. Among authors: parkinson r. Int J Cancer. 2024 May 15;154(10):1794-1801. doi: 10.1002/ijc.34845. Epub 2024 Feb 5. Int J Cancer. 2024. PMID: 38312102 Clinical Trial.
Phase I Study of Adjuvant Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine, Low Dose Cyclophosphamide, and SBRT followed by FFX in High-Risk Resected Pancreatic Ductal Adenocarcinoma.
Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM. Hill CS, et al. Among authors: parkinson r. Int J Radiat Oncol Biol Phys. 2024 Nov 13:S0360-3016(24)03561-2. doi: 10.1016/j.ijrobp.2024.10.039. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39547453
201 results